LIVN - リバノバ （LivaNova PLC） リバノバLIVNのチャート
LIVNの企業情報
| symbol | LIVN |
|---|---|
| 会社名 | LivaNova PLC （リバノバ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 リバノワ（LivaNova PLC）は治療ソリューションの開発に集中する医療機器会社である。同社には、2つの事業セグメントがある。心臓手術事業は心血管手術製品の開発、製造及び販売に従事する。心臓手術製品には、人工肺、心肺装置、自家輸血、機械式心臓弁及び心臓弁がある。神経調節事業は、薬剤耐性てんかん及び治療抵抗性うつ病の治療のための神経調節治療の設計、開発及び販売に従事する。 リバノバはイギリスの医療品企業。主に心臓欠陥疾患の病理を扱う製品と医療サ―ビスに従事する。心臓外科手術と不整脈や心拍管理、心肺バイパス手術のための製品やサ―ビスを提供する他、癲癇や鬱病治療のための神経調整に基づく医療機器を提供する。また、心臓麻痺と僧帽弁閉鎖不全の分野においても、新しい治療法の開発に取り組む。本社所在地はロンドン。 LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. |
| 本社所在地 | 20 Eastbourne Terrace London W2 6LG GBR |
| 代表者氏名 | Daniel Jeffrey Moore ダニエルジェフリームーア |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +44 20-3325-0662 |
| 設立年月日 | 42036 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 4500人 |
| url | www.livanova.com |
| nasdaq_url | https://www.nasdaq.com/symbol/livn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 182.51100 |
| 終値（lastsale） | 118.18 |
| 時価総額（marketcap） | 5742595114.66 |
| 時価総額 | 時価総額（百万ドル） 5519.558 |
| 売上高 | 売上高（百万ドル） 943.68100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 5633.179 |
| 当期純利益 | 当期純利益（百万ドル） 60.54600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 LivaNova PLC revenues increased 11% to $537.9M. Net income before extraordinary items decreased 37% to $37.4M. Revenues reflect Cardiopulmonary segment increase from $107.3M to $261.8M Neuromodulation segment increase of 34% to $204.5M United States segment increase of 10% to $266.1M. Net income was offset by Sell./Gen./Admin. increase of 25% to $227.6M (expense). |
LIVNのテクニカル分析
LIVNのニュース
LivaNova CEO to step down, co sees preliminary Q1 revenue above consensus (NASDAQ:LIVN) 2023/04/14 21:01:46 Seeking Alpha
LivaNova (LIVN) on Friday announced the resignation of its CEO and preliminary Q1 revenue that was above consensus. Read more here.
Barclays maintains LivaNova PLC at Equalweight 2023/04/11 10:08:37 Investing.com
https://www.investing.com/news/pro/livanova-plc-receives-investment-bank-analyst-rating-update-3052312
Pulmonary Valve Replacement Market to Reach USD 1.6 Bn by 2031 | Transparency Market Research 2023/03/28 16:33:00 Accesswire
WILMINGTON, DE / ACCESSWIRE / March 28, 2023 / Transparency Market Research Inc. - The pulmonary valve replacement market was valued at USD 1.0 Bn in 2022 and is projected to surpass USD 1.6 Bn by 2031 with CAGR of 4.9%. Rise in number of transcatheter heart valve replacement procedures in developed countries in the past few years has helped augment the pulmonary valve replacement market size. Advancements in diagnosis of pulmonary valve disorders are likely to bolster the market development. Request for a Sample PDF Report with Latest Industry Insights: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85497 Surge in prevalence of congenital heart diseases (CHD) in adults in several countries is likely to bolster the demand for pulmonary valve replacement procedures. Rapid increase in number of adults with CHD is driving the need for revised guidelines on the management of adult CHD. These guidelines should focus on risk assessment and the type of interventions that would prove effective in the treatment of the disease.
LivaNova PLC: LivaNova to Announce First-Quarter 2023 Results 2023/03/22 13:06:00 Finanz Nachrichten
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m. L…
Results from LivaNova PLC (LIVN) show risk 2023/03/13 12:54:00 US Post News
A share of LivaNova PLC (NASDAQ:LIVN) closed at $41.20 per share on Friday, down from $42.77 day before. While LivaNova PLC has underperformed by -3.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LIVN fell by -43.68%, with highs and lows ranging from $88.00 to $41.82, […]
Cardiac Valve Global Market Report 2022: Ukraine-Russia War Impact 2022/12/20 11:57:00 GlobeNewswire
Major players in the cardiac valve market are LivaNova PLC, Abbott Laboratories , Colibri Heart Valve LLC, TTK HealthCare Limited, Artivion Inc, JenaValve Technology Inc, Edwards Lifesciences Corporation, Lepu Medical Technology Co Ltd, Braile Biomédica, Foldax Inc, Sorin SpA, Neovasc Inc, The RUA Life Sciences group, Translumina Therapeutics Private Limited and On-X Life Technologies. Major players in the cardiac valve market are LivaNova PLC, Abbott Laboratories , Colibri Heart Valve LLC, TTK HealthCare Limited, Artivion Inc, JenaValve Technology Inc, Edwards Lifesciences Corporation, Lepu Medical Technology Co Ltd, Braile Biomédica, Foldax Inc, Sorin SpA, Neovasc Inc, The RUA Life Sciences group, Translumina Therapeutics Private Limited and On-X Life Technologies.
LivaNova PLC: LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration 2022/12/13 21:12:00 Finanz Nachrichten
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received a close-out letter from the U.S. Food and Drug Administration (FDA) for the War…
LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration 2022/12/13 21:05:00 Kwhen Finance
Global and United States Cardiopulmonary Autotransfusion Devices Market to Witness Huge Growth by Key Players: Fresenius Kabi, Haemonetics, LivaNova, Terumo, Stryker 2022/12/06 17:30:24 OpenPR
ReportsnReports publishes the report titled Cardiopulmonary Autotransfusion Devices that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes
Cardiac Pacemakers Global Market Report 2022: Ukraine-Russia War Impact 2022/12/06 13:00:00 PR Newswire
NEW YORK, Dec. 6, 2022 /PRNewswire/ -- Major players in the cardiac pacemakers market are Medtronic Plc, Lepu Medical Technology Co, Abbott Inc, Biotronik SE & Co KG, Boston Scientific Corporation, LivaNova PLC, Medico SRL, Osypka AG, Oscor Inc, MicroPort Scientific Corporation,…
Global and United States Cardiopulmonary Autotransfusion Devices Market to Witness Huge Growth by Key Players: Fresenius Kabi, Haemonetics, LivaNova, Terumo, Stryker 2022/12/06 17:30:24 OpenPR
ReportsnReports publishes the report titled Cardiopulmonary Autotransfusion Devices that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes
Cardiac Pacemakers Global Market Report 2022: Ukraine-Russia War Impact 2022/12/06 13:00:00 PR Newswire
NEW YORK, Dec. 6, 2022 /PRNewswire/ -- Major players in the cardiac pacemakers market are Medtronic Plc, Lepu Medical Technology Co, Abbott Inc, Biotronik SE & Co KG, Boston Scientific Corporation, LivaNova PLC, Medico SRL, Osypka AG, Oscor Inc, MicroPort Scientific Corporation,…
LivaNova PLC (LIVN) can excel with these strategies 2022/11/18 15:16:00 US Post News
As of Thursday, LivaNova PLC’s (NASDAQ:LIVN) stock closed at $52.13, up from $51.35 the previous day. While LivaNova PLC has overperformed by 1.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LIVN fell by -39.36%, with highs and lows ranging from $89.69 to $41.82, whereas the […]